CN101160293A - 脂酶和磷脂酶抑制剂形式的吡咯衍生物 - Google Patents

脂酶和磷脂酶抑制剂形式的吡咯衍生物 Download PDF

Info

Publication number
CN101160293A
CN101160293A CNA2006800127294A CN200680012729A CN101160293A CN 101160293 A CN101160293 A CN 101160293A CN A2006800127294 A CNA2006800127294 A CN A2006800127294A CN 200680012729 A CN200680012729 A CN 200680012729A CN 101160293 A CN101160293 A CN 101160293A
Authority
CN
China
Prior art keywords
alkyl
compound
formula
hydrogen
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800127294A
Other languages
English (en)
Chinese (zh)
Inventor
G·策勒
S·佩特里
G·米勒
H·霍耶尔
N·特纳格尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SRL
Original Assignee
Sanofi Aventis SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101160293(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis SpA filed Critical Sanofi Aventis SpA
Publication of CN101160293A publication Critical patent/CN101160293A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2006800127294A 2005-04-20 2006-04-13 脂酶和磷脂酶抑制剂形式的吡咯衍生物 Pending CN101160293A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005018389A DE102005018389A1 (de) 2005-04-20 2005-04-20 Azolderivate als Inhibitoren von Lipasen und Phospholipasen
DE102005018389.1 2005-04-20

Publications (1)

Publication Number Publication Date
CN101160293A true CN101160293A (zh) 2008-04-09

Family

ID=36694158

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800127294A Pending CN101160293A (zh) 2005-04-20 2006-04-13 脂酶和磷脂酶抑制剂形式的吡咯衍生物

Country Status (20)

Country Link
US (1) US8921404B2 (enExample)
EP (1) EP1874741A1 (enExample)
JP (1) JP2008536884A (enExample)
KR (1) KR20080004501A (enExample)
CN (1) CN101160293A (enExample)
AR (1) AR053228A1 (enExample)
AU (1) AU2006237127A1 (enExample)
BR (1) BRPI0608495A2 (enExample)
CA (1) CA2606301A1 (enExample)
DE (1) DE102005018389A1 (enExample)
IL (1) IL186635A0 (enExample)
MA (1) MA29393B1 (enExample)
MX (1) MX2007012732A (enExample)
MY (1) MY142441A (enExample)
NO (1) NO20075938L (enExample)
NZ (1) NZ562694A (enExample)
RU (1) RU2414458C2 (enExample)
TW (1) TW200722421A (enExample)
WO (1) WO2006111321A1 (enExample)
ZA (1) ZA200707929B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245584A (zh) * 2008-12-15 2011-11-16 艾米拉制药公司 溶血磷脂酶受体的拮抗剂
CN103781792A (zh) * 2011-07-07 2014-05-07 赛诺菲 具有噁唑并[5,4-d]嘧啶环的羧酸衍生物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
KR20090126293A (ko) 2007-04-05 2009-12-08 사노피-아벤티스 리파제 및 포스포리파제 억제제로서의 이미다졸리딘 카복사미드 유도체
BRPI0810044A2 (pt) 2007-04-05 2014-10-14 Sanofi Aventis 5-oxoisoxazóis como inibidores de lipases e fosfolipases
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JP5605844B2 (ja) 2008-10-17 2014-10-15 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
CN102753545A (zh) 2009-12-15 2012-10-24 盐野义制药株式会社 具有血管内皮脂酶抑制活性的噁二唑衍生物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2017034420A1 (en) * 2015-08-27 2017-03-02 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2198457A1 (en) * 1994-08-30 1996-03-07 Koichi Kojima Isoxazole derivatives
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
US6683080B2 (en) * 2001-02-02 2004-01-27 Pfizer Inc. Treatment of diabetes mellitus
AU2001274426A1 (en) 2001-07-04 2003-01-21 Akodi S.A. Web windowed graphical user interface
JP2003033007A (ja) 2001-07-09 2003-01-31 Sanyo Electric Co Ltd チャージポンプ回路の制御方法
US7279470B2 (en) * 2001-12-14 2007-10-09 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
WO2004094394A1 (en) * 2003-04-01 2004-11-04 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
EP1613608A1 (en) * 2003-04-01 2006-01-11 Eli Lilly And Company Phospholipase inhibitors
EP1746991A2 (en) * 2004-03-16 2007-01-31 Janssen Pharmaceutica N.V. Daao inhibiting benzisoxazoles for treating mental disorders
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245584A (zh) * 2008-12-15 2011-11-16 艾米拉制药公司 溶血磷脂酶受体的拮抗剂
CN103781792A (zh) * 2011-07-07 2014-05-07 赛诺菲 具有噁唑并[5,4-d]嘧啶环的羧酸衍生物
CN103781792B (zh) * 2011-07-07 2016-06-29 赛诺菲 具有噁唑并[5,4-d]嘧啶环的羧酸衍生物

Also Published As

Publication number Publication date
BRPI0608495A2 (pt) 2010-01-05
MY142441A (en) 2010-11-30
NO20075938L (no) 2007-11-19
AU2006237127A1 (en) 2006-10-26
JP2008536884A (ja) 2008-09-11
US20080090867A1 (en) 2008-04-17
RU2007142657A (ru) 2009-05-27
US8921404B2 (en) 2014-12-30
CA2606301A1 (en) 2006-10-26
TW200722421A (en) 2007-06-16
NZ562694A (en) 2010-05-28
DE102005018389A1 (de) 2006-10-26
MA29393B1 (fr) 2008-04-01
AR053228A1 (es) 2007-04-25
KR20080004501A (ko) 2008-01-09
RU2414458C2 (ru) 2011-03-20
MX2007012732A (es) 2008-03-14
ZA200707929B (en) 2008-12-31
EP1874741A1 (de) 2008-01-09
WO2006111321A1 (de) 2006-10-26
IL186635A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
CN101160293A (zh) 脂酶和磷脂酶抑制剂形式的吡咯衍生物
US7968719B2 (en) Indazole derivatives as inhibitors of hormone sensitive lipase
US7846943B2 (en) Azolopyridin-2-one derivatives as lipase and phospholipase inhibitors
US7709513B2 (en) Benzooxazol-2-one derivatives as lipase and phospholipase inhibitors
US8008331B2 (en) Benzothiazol-2-one derivatives as lipase and phospholipase inhibitors
HK1119164A (en) Azole derivatives in the form of lipase and phospholipase inhibitors
HK1122277A (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
HK1120796A (en) Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors
HK1120500A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1119164

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080409

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1119164

Country of ref document: HK